FDA approves Hovilpri as novel oral treatment for refractory herpes simplex infections in immunocompromised adults
The FDA has approved Hovilpri, a novel oral helicase-primase inhibitor for refractory mucocutaneous herpes simplex virus infections in immunocompromised adults.
Hovilpri (pritelivir), developed by AiCuris and associated with Asahi Kasei Therapeutics, is approved for patients whose mucocutaneous HSV lesions are refractory to acyclovir, valacyclovir or famciclovir.
The approval introduces a new antiviral mechanism for a difficult-to-treat infection, representing the first FDA-approved treatment with a novel mechanism for this condition in nearly three decades.
Field | Content |
Article Type | Approvals |
Drug Name | Hovilpri |
Generic Name | Pritelivir |
Companies | AiCuris; Asahi Kasei Therapeutics |
Regulatory Authority | U.S. Food and Drug Administration |
Approval Type | New drug approval |
Indication | Refractory mucocutaneous herpes simplex virus infections |
Patient Population | Immunocompromised adults with mucocutaneous HSV lesions refractory to acyclovir, valacyclovir or famciclovir |
Therapy Area | Infectious diseases; virology |
Technology/Modality | Oral helicase-primase inhibitor |
Administration | Oral |
Target Pathogen | Herpes simplex virus |
Refractory Treatment Criteria | Resistance or inadequate response to acyclovir, valacyclovir or famciclovir as described in the approval announcement |
Mechanism of Action | Inhibition of the viral helicase-primase complex involved in HSV DNA replication |
Geography | United States |
What Happened | The FDA approved Hovilpri for immunocompromised adults with refractory mucocutaneous herpes simplex virus infections. |
Why It Matters | The approval provides a novel antiviral mechanism for patients with limited treatment options following failure of established HSV therapies. |
Supporting Context | Hovilpri represents the first FDA-approved treatment with a new mechanism for this condition in nearly 30 years. |
Potential Impact | The oral therapy could expand treatment options for immunocompromised adults with difficult-to-treat mucocutaneous HSV infections. |
Key Takeaway | Hovilpri introduces a new FDA-approved oral antiviral option for refractory HSV infections in immunocompromised adults. |
What to Watch | US commercial availability, prescribing guidance, clinical adoption, reimbursement and real-world effectiveness in refractory HSV infections. |
Primary Source | Asahi Kasei Therapeutics |
Relevant Date | 9 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios